Your session is about to expire
← Back to Search
Ripretinib for Gastrointestinal Stromal Tumors (INTRIGUE Trial)
INTRIGUE Trial Summary
This trial is comparing the effectiveness of ripretinib to sunitinib in patients with gastrointestinal stromal tumors (GIST) who did not respond well to their first treatment with imatin
INTRIGUE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowINTRIGUE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2017 Phase 2 & 3 trial • 78 Patients • NCT01164202INTRIGUE Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any available slots for patients to participate in this research study?
"According to the information provided on clinicaltrials.gov, this particular clinical trial is not currently accepting new participants. The study was initially posted on February 11th, 2019 and had its most recent update on January 4th, 2021. However, it's worth noting that there are presently an additional 44 active studies actively seeking eligible individuals for participation."
At how many different venues is this medical investigation currently accessible?
"Hospital de Basurto in Bilbao, Georgia, Ajou University Hospital in Suwon, Kentucky, and the University of California San Diego Medical Center in La Jolla, Maryland are among the select sites where patients can enroll for this trial. Additionally, there are 120 other locations accepting participants as well."
What is the level of safety associated with DCC-2618 in individuals?
"Based on our assessment at Power, the safety of DCC-2618 is rated as 3. This rating reflects its participation in a Phase 3 trial, indicating that there exists data supporting both efficacy and multiple rounds of safety testing."
Share this study with friends
Copy Link
Messenger